Aiosyn: AI-Driven Digital Pathology for Precision Diagnostics

Aiosyn is a Dutch deep-tech company pioneering the use of artificial intelligence to assist clinical pathologists in diagnosing cancer and kidney diseases. Founded in 2021 as a spin-off from the Radboud University Medical Center in Nijmegen, Aiosyn emerged from one of Europe’s leading computational pathology research groups .

The company develops advanced software that can detect microscopic disease patterns in digital tissue images, aiming to make diagnostics faster and more accurate. Despite its roots in healthcare, Aiosyn’s innovations in AI and imaging position it as a dual-use technology player with implications for European strategic autonomy.

This analysis answers: How does Aiosyn's AI software detect microscopic disease patterns in digital tissue images to assist pathologists diagnosing cancer and kidney diseases? How does Aiosyn's computational-pathology heritage from Radboud University Medical Center translate into a dual-use technology relevant to European strategic autonomy? Which partners, customers and markets does the Dutch deep-tech firm target for its AI and imaging innovations? What capability gaps, IP assets and strategic indicators define Aiosyn's dual-use potential in AI-driven diagnostics?